The Second BHD Symposium was co-sponsored by the Office of Rare Disease Research at NIH and the Myrovlytis Trust, and was held on 22nd April 2010, at the Washington Marriott at Metro Center Hotel, Washington DC, USA.
Dr Laura Schmidt is currently a staff scientist at the Center for Cancer Research, National Cancer Institute, NIH, USA. Dr Schmidt’s research focuses on identifying new genes involved in familial renal cancer. Dr Schmidt was part of the team that cloned the VHL tumor suppressor gene, and that identified mutations in folliculin, the gene mutated in BHD syndrome.
This year’s invited guest speaker was Dr. Berton Zbar, who has over 20 years experience in the field of renal cancer genetics.
Before his retirement, Dr Zbar was chief of the Laboratory of Immunobiology at the Center for Cancer Research, National Cancer Institute, NIH, USA, where he and his colleagues studied families affected with the BHD Syndrome as well as von Hippel-Lindau (VHL) syndrome, hereditary papillary renal carcinoma (HPRC), and Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC).
Dr McCormack is professor at the University of Cincinnati and director of the division of Pulmonary, Critical Care & Sleep Medicine. He is an expert in lymphangioleiomyomatosis (LAM), a progressive lung disease that affects women almost exclusively and is characterised by the development of pulmonary cysts.
The Scientific Committe for the Symposium:
- Dr Laura Schmidt;
- Professor Eamonn Maher;
- Dr Maurice van Steensel; and
- Dr Arnim Pause.